PARAGARD T 380A
Details
- Status
- Prescription
- First Approved
- 1984-11-15
- Routes
- INTRAUTERINE
- Dosage Forms
- SYSTEM
PARAGARD T 380A Approval History
What PARAGARD T 380A Treats
6 FDA approvalsOriginally approved for its first indication in 1984 . Covers 6 distinct patient populations.
- Other (6)
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PARAGARD T 380A FDA Label Details
ProIndications & Usage
FDA Label (PDF)Paragard is indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years.
PARAGARD T 380A Patents & Exclusivity
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.